Search Result

Results for "

JNK

" in MCE Product Catalog:

By Targets:	JNK (69) Akt (11) AMPK (2) Amyloid-β (1) Antibiotic (2) AP-1 (1) Apoptosis (36) Aryl Hydrocarbon Receptor (1) Autophagy (27) Bacterial (3) Bcl-2 Family (1) Beclin1 (1) Calcium Channel (4) Caspase (3) CDK (1) Cholinesterase (ChE) (1) COX (2) Discoidin Domain Receptor (1) DNA/RNA Synthesis (1) E1/E2/E3 Enzyme (1) Endogenous Metabolite (6) ERK (11) Ferroptosis (1) FLT3 (1) FXR (1) Glutathione Peroxidase (1) GSK-3 (2) Gutathione S-transferase (2) HIF/HIF Prolyl-Hydroxylase (1) HIV (5) IKK (1) Interleukin Related (2) IRAK (1) JAK (1) Keap1-Nrf2 (2) LIM Kinase (LIMK) (1) MAP3K (1) MAPKAPK2 (MK2) (2) MDM-2/p53 (2) MEK (1) Microtubule/Tubulin (1) Mitophagy (1) MMP (3) MNK (1) mTOR (1) Na+/Ca2+ Exchanger (1) NF-κB (12) NO Synthase (1) p38 MAPK (18) PAI-1 (1) Parasite (4) PDK-1 (1) Phosphatase (1) Phospholipase (1) PI3K (2) PKA (4) PKC (4) Potassium Channel (3) Prostaglandin Receptor (1) Raf (1) Reactive Oxygen Species (3) Reverse Transcriptase (2) ROCK (4) ROS Kinase (2) SARS-CoV (2) TGF-beta/Smad (1) TGF-β Receptor (1) TNF Receptor (5) Toll-like Receptor (TLR) (2) Topoisomerase (1) TrxR (1) Tyrosinase (2) VEGFR (2) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (74) Cardiovascular Disease (4) Infection (8) Inflammation/Immunology (40) Metabolic Disease (10) Neurological Disease (19)

By Targets:

JNK (69)

Akt (11)

AMPK (2)

Amyloid-β (1)

Antibiotic (2)

AP-1 (1)

Apoptosis (36)

Aryl Hydrocarbon Receptor (1)

Autophagy (27)

Bacterial (3)

Bcl-2 Family (1)

Beclin1 (1)

Calcium Channel (4)

Caspase (3)

CDK (1)

Cholinesterase (ChE) (1)

COX (2)

Discoidin Domain Receptor (1)

DNA/RNA Synthesis (1)

E1/E2/E3 Enzyme (1)

Endogenous Metabolite (6)

ERK (11)

Ferroptosis (1)

FLT3 (1)

FXR (1)

Glutathione Peroxidase (1)

GSK-3 (2)

Gutathione S-transferase (2)

HIF/HIF Prolyl-Hydroxylase (1)

HIV (5)

IKK (1)

Interleukin Related (2)

IRAK (1)

JAK (1)

Keap1-Nrf2 (2)

LIM Kinase (LIMK) (1)

MAP3K (1)

MAPKAPK2 (MK2) (2)

MDM-2/p53 (2)

MEK (1)

Microtubule/Tubulin (1)

Mitophagy (1)

MMP (3)

MNK (1)

mTOR (1)

Na+/Ca2+ Exchanger (1)

NF-κB (12)

NO Synthase (1)

p38 MAPK (18)

PAI-1 (1)

Parasite (4)

PDK-1 (1)

Phosphatase (1)

Phospholipase (1)

PI3K (2)

PKA (4)

PKC (4)

Potassium Channel (3)

Prostaglandin Receptor (1)

Raf (1)

Reactive Oxygen Species (3)

Reverse Transcriptase (2)

ROCK (4)

ROS Kinase (2)

SARS-CoV (2)

TGF-beta/Smad (1)

TGF-β Receptor (1)

TNF Receptor (5)

Toll-like Receptor (TLR) (2)

Topoisomerase (1)

TrxR (1)

Tyrosinase (2)

VEGFR (2)

Wnt (1)

β-catenin (1)

By Research Areas:

Cancer (74)

Cardiovascular Disease (4)

Infection (8)

Inflammation/Immunology (40)

Metabolic Disease (10)

Neurological Disease (19)

125

Inhibitors & Agonists

Screening Libraries

Peptides

Natural
Products

Recombinant Proteins

Isotope-Labeled Compounds

Targets Recommended: JNK

Cat. No.	Product Name	Target	Research Areas

HY-15617

JNK-IN-7
JNK inhibitor
JNK Cancer

JNK-IN-7 is a potent JNK inhibitor with IC₅₀ of 1.5, 2 and 0.7 nM for JNK1, JNK2 and JNK3, respectively.
HY-13319

JNK-IN-8
JNK Inhibitor XVI
JNK Cancer

JNK-IN-8 (JNK Inhibitor XVI) is a potent JNK inhibitor with IC₅₀s of 4.7 nM, 18.7 nM, and 1 nM for JNK1, JNK2, and JNK3, respectively.

JNK-IN-7 JNK inhibitor	JNK	Cancer
JNK-IN-7 is a potent *JNK* inhibitor with IC₅₀ of 1.5, 2 and 0.7 nM for *JNK1, JNK2* and *JNK3*, respectively.

JNK-IN-8 JNK Inhibitor XVI	JNK	Cancer
JNK-IN-8 (JNK Inhibitor XVI) is a potent *JNK* inhibitor with IC₅₀s of 4.7 nM, 18.7 nM, and 1 nM for *JNK1, JNK2, and JNK3*, respectively.

HY-107598

JNK Inhibitor VIII TCS JNK 6o	JNK	Cancer
JNK Inhibitor VIII (TCS JNK 6o) is a *c-Jun N-terminal kinases (JNK-1, -2, and -3)* inhibitor with K_i values of 2 nM, 4 nM, 52 nM, respectively, and has IC₅₀ values of 45 nM and 160 nM for JNK-1 and -2, respectively.

HY-15881

TCS JNK 5a
JNK Inhibitor IX
JNK Apoptosis Cancer

TCS JNK 5a is a potent JNK3 inhibitor with a pIC₅₀ of 6.7. TCS JNK 5a also inhibits JNK2 with a pIC₅₀ of 6.5.

*TCS JNK* 5a** JNK Inhibitor IX	JNK Apoptosis	Cancer
TCS JNK 5a is a potent *JNK3* inhibitor with a pIC₅₀ of 6.7. TCS JNK 5a also inhibits *JNK2* with a pIC₅₀ of 6.5.

HY-13319G

JNK-IN-8 JNK Inhibitor XVI	JNK	Cancer
JNK-IN-8 (JNK Inhibitor XVI) (GMP) is JNK-IN-8 (HY-13319) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. JNK-IN-8 is a potent *JNK* inhibitor with IC₅₀s of 4.7 nM, 18.7 nM, and 1 nM for *JNK1, JNK2, and JNK3*, respectively.

HY-150053

JNK-IN-11	JNK	Neurological Disease
JNK-IN-11 (compound 1) is a potent *JNK* inhibitor with an IC₅₀ value of 2.2, 21.4, 1.8 µM for JNK1, JNK2, JNK3, respectively. JNK-IN-11 has the potential for the research of alzheimer and parkinson disease.

HY-150552

JNK3 inhibitor-2	JNK Discoidin Domain Receptor	Cancer Inflammation/Immunology
JNK3 inhibitor-2 is a potent and selective *JNK3* inhibitor with IC₅₀ values of >100, >100, 0.25 µM for JNK1, JNK2, JNK3, respectively. JNK3 inhibitor-2 shows DDR1 and EGFR (T790M, L858R) inhibition.

HY-151928

JNK3 inhibitor-3	JNK	Neurological Disease
JNK3 inhibitor-3 (compound 15g) is a selective, BBB permeable and orally active c-Jun N-terminal kinase 3 (JNK3) inhibitor. JNK3 inhibitor-3 has inhibitory activities to JNK1, JNK2 and JNK3 with IC₅₀ values of 147.8, 44.0 and 4.1 nM, respectively. JNK3 inhibitor-3 significantly improves the memory in mouse dementia model. JNK3 inhibitor-3 can be used for the research of Alzheimer’s disease.

HY-139624

JNK3 inhibitor-1
JNK Others

JNK3 inhibitor-1 is a potent and selective JNK3 inhibitor (IC₅₀ = 0.005 μM). JNK3 inhibitor-1 is orally bioavailable and brain penetrant.

JNK3 inhibitor-1	JNK	Others
JNK3 inhibitor-1 is a potent and selective *JNK3* inhibitor (IC₅₀ = 0.005 μM). JNK3 inhibitor-1 is orally bioavailable and brain penetrant.

HY-151962

JNK3 inhibitor-5	JNK Apoptosis GSK-3 p38 MAPK	Neurological Disease
JNK3 inhibitor-5 (Compound 22b) is a potent and selective *JNK3* inhibitor with an IC₅₀ of 0.379 nM. JNK3 inhibitor-5 effectively protects the neuronal cells against amyloid beta-induced apoptosis. JNK3 inhibitor-5 has a high cell permeability and is predicted as BBB permeable.

HY-151929

JNK3 inhibitor-4	JNK	Neurological Disease
JNK3 inhibitor-4 is a potent inhibitor of *JNK3* (IC₅₀=1.0 nM) based on 2-aryl-1-pyrimidinyl-1H-imidazole-5-yl acetonitrile. JNK3 inhibitor-4 shows excellent selectivity over other protein kinases including isoforms *JNK1* (IC₅₀=143.9 nM) and *JNK2* (IC₅₀=298.2 nM). JNK3 inhibitor-4 has neuroprotective effect and predicated blood-brain barrier permeability.

HY-112402

SP 600125, negative control JNK Inhibitor II, negative control	Others	Cancer
SP 600125, negative control (SPM1) is an alkyl derivative of pyrazoloanthrone, which can be used as a negative control for SP600125 (HY-12041).

HY-147836

*Akt/NF-κB/JNK-IN-1*	Akt NF-κB JNK TNF Receptor COX	Inflammation/Immunology
Akt/NF-κB/JNK-IN-1 (Compound 2i) is an inhibitor of Akt, NF-κB and *JNK* signaling pathways. Akt/NF-κB/JNK-IN-1 inhibits nitric oxide production with an IC₅₀ of 3.15 μM. Akt/NF-κB/JNK-IN-1 shows anti-inflammatory activities.

HY-144761

*TOPK-p38/JNK-IN-1*	JNK	Cancer
TOPK-p38/JNK-IN-1 (Compound B12) is an orally active *TOPK-p38/JNK* signaling pathway inhibitor with the IC₅₀ value of 2.14 µM for NO production. TOPK-p38/JNK-IN-1 shows anti-inflammatory activities. TOPK-p38/JNK-IN-1 also inhibits phosphorylate downstream related proteins and avoids degradation of TOPK.

HY-N11536

erythro-Austrobailignan-6	Topoisomerase Apoptosis	Cancer
erythro-Austrobailignan-6 is an orally active anti-cancer agent. erythro-Austrobailignan-6 inhibits DNA topoisomerase I and II activity. erythro-Austrobailignan-6 induces cell apoptosis and increases phosphorylation of p38 and JNK.

HY-138304

CC-90001	JNK	Inflammation/Immunology
CC-90001 is a potent, selective and orally active inhibitor of c-Jun N-terminal kinase (JNK). CC-90001 shows 12.9-fold selectivity for *JNK1* over *JNK2* in a cell-based model. CC-90001 can be used for the research of idiopathic pulmonary fibrosis.

HY-N3828

epi-Eriocalyxin A	Apoptosis ERK JNK	Cancer
epi-Eriocalyxin A (Epieriocalyxin A), a diterpenoid isolated from Isodon eriocalyx, induces colon cancer apoptosis. epi-Eriocalyxin A also inhibits ERK1/2 and *JNK* activation, which suppresses Bcl-2 expression.

HY-11010

AS601245	JNK	Cancer Inflammation/Immunology Neurological Disease
AS601245 is an orally active, selective, ATP competitive JNK (c-Jun NH2-terminal protein kinase) inhibitor with IC₅₀s of 150, 220, and 70 nM for three JNK human isoforms (hJNK1, hJNK2, and hJNK3), respectively. AS601245 exhibits 10- to 20-fold selectivity over c-src, CDK2, and c-Raf and more than 50- to 100-fold selectivity over a range of Ser/Thr- and Tyr-protein kinases. Neuroprotective properties.

HY-152774

Antitumor agent-86	Akt PI3K	Cancer
Antitumor agent-86 (compound 5a) inhibits MCF-7 breast cancer cells with an IC₅₀ value of 2.62 µM. Antitumor agent-86 induces cell apoptosis and cell cycle arrest, and shows antineoplastic activity by targeting *RAS/PI3K/Akt/JNK* signaling cascades.

HY-13634

Ezatiostat hydrochloride TER199; TLK199 hydrochloride	Gutathione S-transferase Apoptosis	Cancer
Ezatiostat hydrochloride (TER199; TLK199 hydrochloride) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat hydrochloride leads to JNK activation by inhibiting GSTP1. Ezatiostat hydrochloride stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat hydrochloride has the potential for myelodysplastic syndrome (MDS) treatment.

HY-13634A

Ezatiostat TER199(free base); TLK199	Gutathione S-transferase Apoptosis	Cancer
Ezatiostat (TER199 free base; TLK199) is a tripeptide analog of glutathione and is a selective and orally active glutathione S-transferase P1-1 (GSTP1) inhibitor. Ezatiostat leads to JNK activation by inhibiting GSTP1. Ezatiostat stimulates both lymphocyte production and bone marrow progenitor proliferation. Ezatiostat has the potential for myelodysplastic syndrome (MDS) treatment.

HY-134000

Emodic acid NSC624610	p38 MAPK NF-κB ERK JNK VEGFR MMP	Cancer
Emodic acid (NSC624610) is an anthraquinone compound isolated from A. microcarpus, which can inhibit the proliferation of cancer cells by inhibiting the activity of NF-κB. Emodic acid can also inhibit the phosphorylation of p38, ERK and *JNK, the secretion of tumor-promoting cytokines IL-1β and IL-6, and the expression of VEGF* and MMP, thereby inhibiting the invasion and migration potential of cancer cells.

HY-14761

Bentamapimod
AS 602801
JNK Cancer

Bentamapimod (AS 602801) is an ATP-competitive JNK inhibitor with IC₅₀ of 80 nM, 90 nM, and 230 nM for JNK1, JNK2, and JNK3, respectively.

Bentamapimod AS 602801	JNK	Cancer
Bentamapimod (AS 602801) is an ATP-competitive *JNK* inhibitor with IC₅₀ of 80 nM, 90 nM, and 230 nM for *JNK1, JNK2, and JNK3*, respectively.

HY-107599

AEG3482	JNK Apoptosis	Neurological Disease
AEG3482 is a potent antiapoptotic compound that inhibits Jun kinase (JNK) activity through induced expression of heat shock protein 70 (HSP70). AEG3482 directly binds HSP90, thereby facilitating HSF1-dependent expression of HSP70 and HSP25.

HY-P2246

JTP10-△-TATi TFA
JNK Cancer

JTP10-△-TATi TFA is a selective JNK2 peptide inhibitor, with an IC₅₀ of 92 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.
HY-P2247

JTP10-△-R9 TFA
JNK Cancer

JTP10-△-R9 TFA is a selective JNK2 peptide inhibitor, with an IC₅₀ of 89 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.

JTP10-△-TATi TFA	JNK	Cancer
JTP10-△-TATi TFA is a selective *JNK2* peptide inhibitor, with an IC₅₀ of 92 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.

JTP10-△-R9 TFA	JNK	Cancer
JTP10-△-R9 TFA is a selective *JNK2* peptide inhibitor, with an IC₅₀ of 89 nM, exhibiting 10-fold selectivity for JNK2 over JNK1 and JNK3.

HY-113756A

Latanoprost acid	Prostaglandin Receptor	Inflammation/Immunology
Latanoprost acid, an analog of prostaglandin (PG) F2α, is an selective prostanoid receptor (FP) agonist that specifically activates the FP-PG receptor. Latanoprost acid inhibits RANKL-induced osteoclastgenesis and function by inhibiting ERK, AKT, JNK, and p38 cascade, following by the c-fos/NFATc1 pathway. Latanoprost acid is a medication which works to lower pressure inside the eyes.

HY-13275

IRAK inhibitor 1	IRAK	Inflammation/Immunology
IRAK inhibitor 1 is a potent IRAK-4 inhibitor with IC₅₀ of 216 nM, is poorly active against JNK-1 and JNK-2 with IC₅₀ of 3.801 μM, and >10 μM, respectively.

HY-107600

IQ-3	JNK	Inflammation/Immunology
IQ-3 is a specific inhibitor of the c-Jun N-terminal kinase (JNK) family, with preference for JNK3. IQ-3 exhibits K_d values of 0.24 μM, 0.29 μM and 0.066 μM for JNK1, JNK2 and JNK3, respectively.

HY-N7394A

(-)-Zuonin A D-Epigalbacin	JNK	Cancer
(-)-Zuonin A (D-Epigalbacin), a naturally occurring lignin, is a potent, selective *JNKs* inhibitor, with IC₅₀s of 1.7 μM, 2.9 μM and 1.74 μM for JNK1, JNK2 and JNK3, respectively.

HY-146323

Antitumor agent-58	Apoptosis	Cancer
Antitumor agent-58 (Compound C18) is an anti-tumor agent. Antitumor agent-58 effectively inhibits colony formation and cell migration of MGC-803 cells. Antitumor agent-58 induces apoptosis of MGC-803 cells through activation of the p38 and JNK signaling pathways. Antitumor agent-58 induces mitochondrial dysfunction of MGC-803 cells. Antitumor agent-58 effectively inhibits tumor growth of xenograft model bearing MGC-803 cells.

HY-12041

SP600125	JNK Autophagy Apoptosis Ferroptosis	Cancer
SP600125 is an orally active, reversible, and ATP-competitive *JNK* inhibitor with IC₅₀s of 40, 40 and 90 nM for *JNK1, JNK2* and *JNK3, respectively. SP600125 is a potent ferroptosis* inhibitor. SP600125 inhibits autophagy and activates apoptosis.

HY-100233

IQ-1S free acid	JNK	Cancer Inflammation/Immunology
IQ-1S free acid is a prospective inhibitor of NF-κB/activating protein 1 (AP-1) activity with an IC₅₀ of 2.3±0.41 μM. IQ-1S free acid has binding affinity (K_d values) in the nanomolar range for all three *JNKs with K_ds of 100 nM, 240 nM, and 360 nM for JNK3, JNK1, and JNK2*, respectively.

HY-15495

Tanzisertib
CC-930
JNK Inflammation/Immunology

Tanzisertib (CC-930) is a potent JNK1/2/3 inhibitor with IC₅₀s of 61/7/6 nM, respectively.
HY-10366

BI-78D3
JNK Metabolic Disease Cancer

BI-78D3 functions as a substrate competitive inhibitor of JNK, inhibit the JNK kinase activity (IC₅₀=280 nM).

Tanzisertib CC-930	JNK	Inflammation/Immunology
Tanzisertib (CC-930) is a potent *JNK1/2/3* inhibitor with IC₅₀s of 61/7/6 nM, respectively.

BI-78D3	JNK	Metabolic Disease Cancer
BI-78D3 functions as a substrate competitive inhibitor of *JNK, inhibit the JNK* kinase activity (IC₅₀=280 nM).

HY-107597

SU3327	JNK	Metabolic Disease Inflammation/Immunology
SU3327 is a potent, selective and substrate-competitive *JNK* inhibitor with an IC₅₀ of 0.7 μM. SU3327 also inhibits protein-protein interactions between *JNK* and JNK Interacting Protein (JIP) with an IC₅₀ of 239 nM. SU3327 shows less active against p38α and Akt kinase.

HY-N0773

Isovitexin Saponaretin; Homovitexin	JNK NF-κB	Inflammation/Immunology
Isovitexin is a flavonoid isolated from passion flower, Cannabis and, and the palm, possesses anti-inflammatory and anti-oxidant activities; Isovitexin acts like a *JNK1/2* inhibitor and inhibits the activation of NF-κB.

HY-125838

J30-8	JNK	Neurological Disease
J30-8 is a potent and isoform-selective inhibitor of c-Jun N-terminal kinase 3 (JNK3) with an IC₅₀ of 40 nM, which 2500-fold isoform selectivity against JNK1α1 and JNK2α2. J30-8 exhibits neuroprotective activity in vitro and potential for the treatment of neurodegenerative diseases.

HY-10412

CEP-1347
KT7515
JAK Neurological Disease

CEP-1347 is an inhibitor of the JNK/SAPK pathway with neuroprotective effects.

CEP-1347 KT7515	JAK	Neurological Disease
CEP-1347 is an inhibitor of the *JNK/SAPK* pathway with neuroprotective effects.

HY-139254

Indirubin-3′-oxime IDR3O; I3O	CDK GSK-3 JNK	Neurological Disease
Indirubin-3′-oxime (IDR3O), a synthetic derivative of indirubin, is a potent inhibitor of cyclin-dependent kinases (CDKs) and glycogen synthase kinase 3β (GSK3β). Indirubin-3′-oxime directly inhibits the activity of all three isoforms of JNK (JNK1, JNK2, and JNK3), with IC₅₀s of 0.8 μM, 1.4 μM, and 1.0 μM, respectively. Indirubin-3′-oxime can enhance height growth via activation of Wnt/β-catenin signaling in chondrocytes.

HY-P1191

JIP-1(153-163) T1-JIP	JNK	Others
JIP-1(153-163) (TI-JIP) is a peptide inhibitor of *c-JNK, based on residues 153-163 of JNK*-interacting protein-1 (JIP-1) (Modifications: Phe-11 = C-terminal amide).

HY-P0069A

L-JNKI-1
JNK Neurological Disease

L-JNKI-1 is a cell-permeable peptide inhibitor specific for JNK.
HY-15737

DB07268
JNK Cancer

DB07268 is a potent and selective JNK1 inhibitor with an IC₅₀ value of 9 nM.
HY-12829

SR-3306
JNK Neurological Disease

SR-3306 is a selective, potent, highly brain penetrant JNK inhibitor.

L-JNKI-1	JNK	Neurological Disease
L-JNKI-1 is a cell-permeable peptide inhibitor specific for *JNK*.

DB07268	JNK	Cancer
DB07268 is a potent and selective *JNK1* inhibitor with an IC₅₀ value of 9 nM.

SR-3306	JNK	Neurological Disease
SR-3306 is a selective, potent, highly brain penetrant *JNK* inhibitor.

HY-18982

Anisomycin Flagecidin; Wuningmeisu C	DNA/RNA Synthesis JNK Bacterial Apoptosis Antibiotic Parasite	Cancer Infection
Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system. Anisomycin is a *JNK* activator, which increases phospho-JNK. Anisomycin is a bacterial antibiotic.

HY-P1191A

JIP-1(153-163) TFA T1-JIP TFA	JNK	Others
JIP-1(153-163) TFA (TI-JIP TFA) is a peptide inhibitor of *c-JNK, based on residues 153-163 of JNK*-interacting protein-1 (JIP-1) (Modifications: Phe-11 = C-terminal amide).

HY-13022A

CC-401
JNK Cancer

CC-401 is a potent inhibitor of all three forms of JNK with K_i of 25 to 50 nM.
HY-13022

CC-401 hydrochloride
CC401 HCl
JNK Cancer

CC-401 hydrochloride is a potent inhibitor of all three forms of JNK with K_i of 25 to 50 nM.

HY-120349

LL-Z1640-4	p38 MAPK JNK Apoptosis Reactive Oxygen Species	Cancer
LL-Z1640-4 is a potent *p38/JNK* signaling inhibitor. LL-Z1640-4 significantly diminishes p38 and *JNK* activation in HCC cells transfected with MLK4 siRNA. LL-Z1640-4 markedly attenuates ROS production induced by MLK4 knockdown. LL-Z1640-4 significantly reduces the apoptotic cells in HCC cells transfected with siMLK4.

HY-10542

GW 5074	Raf Apoptosis	Cancer
GW 5074 is a potent and selective c-Raf inhibitor with IC₅₀ of 9 nM, and has no effect on the activities of JNK1/2/3, MEK1, MKK6/7, CDK1/2, c-Src, p38 MAP, VEGFR2 or c-Fms.

HY-P0069

D-JNKI-1
AM-111; XG-102
JNK Others

D-JNKI-1 (AM-111) is a highly potent and cell-permeable peptide inhibitor of JNK.
HY-107596

SR-3576
JNK Others

SR-3576 is a highly potent and selective JNK3 inhibitor with an IC₅₀ of 7 nM.

HY-147513

AKT-IN-12	Akt Apoptosis	Cancer
AKT-IN-12 (compound 3e) is a potent Akt kinase inhibitor with an IC₅₀ value of 0.55 μM. AKT-IN-12 induces G0/G1 cell cycle arrest and apoptosis. AKT-IN-12 also inhibits p-AKT, p-ERK, and activates p-JNK, JNK. AKT-IN-12 can be used for researching leukemia.

HY-N2205

Esculentoside H	NF-κB JNK	Cancer
Esculentoside H (EsH) is a saponin isolated from the root extract of perennial plant Phytolacca esculenta. Esculentoside H (EH) has anti-tumor activity, the mechanism is related to the capacity for TNFrelease. Esculentoside H (EsH) suppresses colon cancer cell migration through blockage of the JNK1/2 and NF-κB signaling-mediated matrix metalloproteinases-9 (MMP-9) expression.

HY-N3442

Juglanin	JNK Apoptosis Autophagy	Cancer Inflammation/Immunology
Juglanin, a natural occurring flavonoid, is a *JNK* acticator, with inflammation and anti-tumor activities. Juglanin can induce apoptosis and autophagy on human breast cancer cells.

HY-N2149A

Tomatidine hydrochloride	NF-κB JNK Autophagy Endogenous Metabolite	Inflammation/Immunology Cardiovascular Disease
Tomatidine hydrochloride acts as an anti-inflammatory agent by blocking NF-κB and *JNK* signaling. Tomatidine hydrochloride activates autophagy either in mammal cells or C elegans.

HY-N2149

Tomatidine	NF-κB JNK Autophagy Endogenous Metabolite	Inflammation/Immunology Cardiovascular Disease
Tomatidine acts as an anti-inflammatory agent by blocking NF-κB and *JNK* signaling. Tomatidine activates autophagy either in mammal cells or C elegans.

HY-103640

Amifostine thiol dihydrochloride WR-1065 dihydrochloride	MDM-2/p53	Cancer
Amifostine thiol (WR-1065) dihydrochloride can protect normal tissues from the toxic effects of certain cancer drugs and activate p53 through a JNK-dependent signaling pathway.

HY-150688

JAK3-IN-13	JNK	Cancer
JAK3-IN-13 is a potent, selective and orally active JAK3 inhibitor with IC₅₀ values of 4728, 2039, 8, 365 nM for NK1, JNK2, JNK3, Tyk2, respectively. JAK3-IN-13 shows antiproliferative activity. JAK3-IN-13 induces cell cycle arrest at G0/G1 phase. JAK3-IN-13 shows antitumor activity.

HY-N1966

(E)-Osmundacetone	p38 MAPK JNK ERK	Neurological Disease
(E)-Osmundacetone is the isomer of Osmundacetone. Osmundacetone significantly suppresses the phosphorylation of MAPKs, including JNK, ERK, and p38 kinases. Osmundacetone has a neuroprotective effect against oxidative stress.

HY-101287

MPT0B392	Microtubule/Tubulin JNK Apoptosis Caspase	Cancer
MPT0B392, an orally active quinoline derivative, induces *c-Jun N-terminal kinase (JNK)* activation, leading to apoptosis. MPT0B392 inhibits tubulin polymerization and triggers induction of the mitotic arrest, followed by mitochondrial membrane potential loss and caspases cleavage by activation of JNK and ultimately leads to apoptosis. MPT0B392 is demonstrated to be a novel microtubule-depolymerizing agent and enhances the cytotoxicity of sirolimus in sirolimus-resistant acute leukemic cells and the multidrug resistant cell line.

HY-136901

Fusarochromanone FC-101	Reactive Oxygen Species	Cancer Cardiovascular Disease
Fusarochromanone (FC-101) is a fungal metabolite with potent anti-angiogenic and anti-cancer activity. Fusarochromanone-activated JNK pathway is attributed to induction of reactive oxygen species (ROS).

HY-N0044

Ginsenoside Re Ginsenoside B2; Panaxoside Re; Sanchinoside Re	Amyloid-β NF-κB JNK Endogenous Metabolite	Inflammation/Immunology Neurological Disease Cancer
Ginsenoside Re (Ginsenoside B2) is an extract from Panax notoginseng. Ginsenoside Re decreases the β-amyloid protein (Aβ). Ginsenoside Re plays a role in antiinflammation through inhibition of *JNK* and NF-κB.

HY-N0052A

Sanguinarine chloride Sanguinarin chloride; Sanguinarium chloride; Pseudochelerythrine chloride	Apoptosis Autophagy Bacterial Parasite	Cancer
Sanguinarine (Sanguinarin) chloride, a benzophenanthridine alkaloid derived from the root of Sanguinaria Canadensis, can stimulate apoptosis via activating the production of reactive oxygen species (ROS). Sanguinarine-induced apoptosis is associated with the activation of JNK and NF-κB.

HY-N6826

Asatone	NF-κB	Inflammation/Immunology
Asatone is an active component isolated from Radix et Rhizoma Asari, with anti-inflammatory effect via activation of NF-κB and donwn regulation of p-MAPK (ERK, JNK and p38) pathways.

HY-N0052

Sanguinarine Sanguinarin; Sanguinarium; Pseudochelerythrine	Apoptosis Autophagy	Cancer
Sanguinarine (Sanguinarin), a benzophenanthridine alkaloid derived from the root of Sanguinaria Canadensis, can stimulate apoptosis via activating the production of reactive oxygen species (ROS). Sanguinarine-induced apoptosis is associated with the activation of JNK and NF-κB.

HY-P2319

OVA-E1 peptide	p38 MAPK JNK	Inflammation/Immunology
OVA-E1 peptide, is an antagonist variant of SIINFEKL [OVA (257-264). OVA-E1 peptide, activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes.

HY-N0819

Raddeanin A	Apoptosis	Cancer
Raddeanin A is a natural triterpenoid saponin component of Anemone raddeana, with anti-cancer activities. Raddeanin A exerts anticancer effect on human osteosarcoma via the ROS/JNK and NF-κB signal pathway.

HY-P2319A

OVA-E1 peptide TFA	p38 MAPK JNK	Inflammation/Immunology
OVA-E1 peptide TFA, is an antagonist variant of SIINFEKL [OVA (257-264). OVA-E1 peptide, activates the p38 and JNK cascades similarly in mutant and wild-type thymocytes.

HY-N0431

Astragaloside IV	MMP ERK JNK	Cancer
Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and *JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9* in MDA-MB-231 breast cancer cells.

HY-17437A

Mefloquine hydrochloride Mefloquin hydrochloride	Parasite SARS-CoV Autophagy Potassium Channel ROS Kinase	Cancer Infection Metabolic Disease Inflammation/Immunology
Mefloquine hydrochloride (Mefloquin hydrochloride), a quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine hydrochloride is also a K⁺ channel (KvQT1/minK) antagonist with an IC₅₀ of ~1 μM. Mefloquine hydrochloride can be used for malaria, systemic lupus erythematosus and cancer research.

HY-10520

CGP 57380	MNK Apoptosis	Cancer
CGP 57380 is a cell-permeable pyrazolo-pyrimidine compound that acts as a selective inhibitor of Mnk1 with IC₅₀ of 2.2 μM, but has no inhibitory activity against p38, JNK1, ERK1/2, PKC, or Src-like kinases.

HY-N1504

Loureirin B	PAI-1 Potassium Channel ERK JNK	Metabolic Disease
Loureirin B, a flavonoid extracted from Dracaena cochinchinensis, is an inhibitor of plasminogen activator inhibitor-1 (PAI-1), with an IC₅₀ of 26.10 μM; Loureirin B also inhibits K_ATP, the phosphorylation of ERK and *JNK*, and has anti-diabetic activity.

HY-N3711

Dehydrocrenatine	JNK ERK Apoptosis	Neurological Disease
Dehydrocrenatidine, a β-carboline alkaloid that can be isolated from Picrasma quassioides. Dehydrocrenatidine induces cell apoptosis by activates ERK and *JNK*. Dehydrocrenatidine inhibits invasion and migration of cancer cells, it also suppresses neuronal excitability to exert analgesic effects.

HY-137864

Amifostine thiol WR-1065	MDM-2/p53	Cancer
Amifostine thiol (WR-1065) is an active metabolite of the cytoprotector Amifostine (HY-B0639). Amifostine thiol is a cytoprotective agent with radioprotective abilities. Amifostine thiol activates p53 through a JNK-dependent signaling pathway.

HY-N6872

Actein	JNK Akt Apoptosis Autophagy	Cancer
Actein is a triterpene glycoside isolated from the rhizomes of Cimicifuga foetida. Actein suppresses cell proliferation, induces autophagy and apoptosis through promoting *ROS/JNK* activation, and blunting AKT pathway in human bladder cancer. Actein has little toxicity in vivo.

HY-19353

SR7826	LIM Kinase (LIMK)	Cancer Neurological Disease
SR7826 is a class of bis-aryl urea derived potent, selective and orally active LIM kinase (LIMK) inhibitor with an IC₅₀ of 43 nM for LIMK1. SR7826 is >100-fold more selective for LIMK1 than ROCK and JNK kinases.

HY-137397

8-Hydroxyefavirenz 8-OH-EFV	Apoptosis JNK	Cancer
8-Hydroxyefavirenz (8-OH-EFV) is a primary metabolite of Efavirenz (HY-10572). 8-Hydroxyefavirenz induces apoptosis via a JNK- and BimEL-dependent mechanism in primary human hepatocytes. 8-Hydroxyefavirenz can be used in research of cancer.

HY-N2375

L-Quebrachitol	Wnt β-catenin	Metabolic Disease
L-Quebrachitol is a natural product isolated from many plants, promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and Wnt/β-catenin signaling pathway.

HY-15415

KB-R7943 mesylate	Na+/Ca2+ Exchanger Autophagy	Cancer
KB-R7943 mesylate is a widely used inhibitor of the reverse Na⁺/Ca²⁺ exchanger (NCX_rev) with IC₅₀ of 5.7±2.1 µM. KB-R7943 mesylate induces cancer cell death via activating the JNK pathway and blocking autophagic flux.

HY-103258

TC ASK 10	MAP3K Apoptosis	Cancer
TC ASK 10 (Compound 10) is a potent, selective and orally active apoptosis signal-regulating kinase 1 (ASK1) inhibitor with an IC₅₀ of 14 nM. The inhibitory activities of TC ASK 10 towards other representative panel of kinases are less than 50%, except for ASK2 (IC₅₀ of 0.51 μM).

HY-146195

MAPK-IN-1	Toll-like Receptor (TLR) p38 MAPK JNK ERK Cholinesterase (ChE)	Inflammation/Immunology Neurological Disease
MAPK-IN-1 (Compound 2) is a MAPK signaling pathway inhibitor. MAPK-IN-1 exhibits AChE inhibitory activity with an IC₅₀ of 23.84 μM. MAPK-IN-1 shows anti-neuroinflammatory and neuroprotective activity and can be used for Alzheimer's disease research.

HY-N0809

Sesamolin	p38 MAPK JNK Caspase	Metabolic Disease Neurological Disease
Sesaminol, isolated from Sesamum indicum, has antioxidative activity, Sesaminol inhibits lipid peroxidation and shows neuroprotection effect. Sesaminol potently inhibits MAPK cascades by preventing phosphorylation of *JNK, p38 MAPKs, and caspase-3* but not ERK-MAPK expression.

HY-14266

Dapivirine TMC120; R147681	HIV Reverse Transcriptase Apoptosis Autophagy	Infection
Dapivirine (TMC120), the prototype of diarylpyrimidines (DAPY), is an orally active and nonnucleoside reverse transcriptase inhibitor (NRTI). Dapivirine (TMC120) binds directly to HIV-1 reverse transcriptase. Dapivirine (TMC120) regulates autophagy and induced Akt, Bad and SAPK/JNK activations.

HY-10403

PH-797804	p38 MAPK Autophagy	Inflammation/Immunology Cancer
PH-797804 is a ATP-competitive, selective p38α/p38β inhibitor (IC₅₀=26 nM and K_i=5.8 nM for p38α; K_i=40 nM for p38β) and does not inhibit JNK2.

HY-N2208

4-Hydroxylonchocarpin	p38 MAPK	Cancer Infection Metabolic Disease Inflammation/Immunology
4-Hydroxylonchocarpin is a chalcone compound from an extract of Psoralea corylifolia. 4-Hydroxylonchocarpin increases phosphorylation of p38 MAPK, JNK and ERK. 4-Hydroxylonchocarpin has diverse pharmacological activities, including antibacterial, antifungal, anticancer, antireverse transcriptase, antitubercular, antimalarial, anti-inflammatory and antioxidant activities.

HY-10405

Pamapimod Ro4402257; R1503	p38 MAPK Autophagy	Inflammation/Immunology
Pamapimod (Ro4402257) is a potent, selective and orally active p38 MAPK inhibitor with IC₅₀s of 14 nM and 480 nM and K_is of 1.3 nM and 120 nM for p38α and p38β, respectively. Pamapimod has no activity against p38δ or p38γ isoforms. Pamapimod has the potential for rheumatoid arthritis and other autoimmune diseases treatment.

HY-126307

Urolithin B	NF-κB JNK ERK Akt AMPK Endogenous Metabolite	Inflammation/Immunology
Urolithin B is one of the gut microbial metabolites of ellagitannins, and has anti-inflammatory and antioxidant effects. Urolithin B inhibits NF-κB activity by reducing the phosphorylation and degradation of IκBα, and suppresses the phosphorylation of *JNK, ERK, and Akt, and enhances the phosphorylation of AMPK*. Urolithin B is also a regulator of skeletal muscle mass.

HY-N0047

Polyphyllin I	JNK mTOR Akt PDK-1 Autophagy Apoptosis	Cancer
Polyphyllin I is a bioactive constituent extracted from Paris polyphylla, has strong anti-tumor activity. Polyphyllin I is an activator of the *JNK* signaling pathway and is an inhibitor of PDK1/Akt/mTOR signaling. Polyphyllin I induces autophagy, G2/M phase arrest and apoptosis.

HY-14266S

Dapivirine-d11 TMC120-d₁₁; R147681-d₁₁	HIV Reverse Transcriptase Apoptosis Autophagy	Infection
Dapivirine-d₁₁ is the deuterium labeled Dapivirine. Dapivirine (TMC120), the prototype of diarylpyrimidines (DAPY), is an orally active and nonnucleoside reverse transcriptase inhibitor (NRTI). Dapivirine (TMC120) binds directly to HIV-1 reverse transcriptase. Dapivirine (TMC120) regulates autophagy and induced Akt, Bad and SAPK/JNK activations[1][2].

HY-N7110

6-Hydroxyflavone	Akt ERK JNK	Inflammation/Immunology
6-Hydroxyflavone is a naturally occurring flavone, with anti-inflammatory activity. 6-Hydroxyflavone exhibits inhibitory effect towards bovine hemoglobin (BHb) glycation. 6-Hydroxyflavone can activate AKT, ERK 1/2, and JNK signaling pathways to effectively promote osteoblastic differentiation. 6-Hydroxyflavone inhibits the LPS-induced NO production .

HY-148510

HKB99	Phosphatase	Cancer
HKB99 is an allosteric inhibitor of phosphoglycerate mutase 1 (PGAM1). HKB99 inhibits the formation of invasive pseudopodia and increases the level of PAI-2 in vitro. HKB99 increases the oxidative stress, activates JNK/c-Jun and suppresses AKT and ERK. HKB99 can be used for the research of non-small-cell lung cancer (NSCLC).

HY-135318

NBDHEX	Glutathione Peroxidase Apoptosis Autophagy	Cancer
NBDHEX is a potent glutathione S-transferase P1-1 (GSTP1-1) inhibitor. NBDHEX induces apoptosis of tumor cells. NBDHEX acts as an anticancer agent by inhibiting GSTs catalytic activity, avoiding inconvenience of the inhibitor extrusion from the cell by specific pumps and disrupting the interaction between the GSTP1-1 and key signaling effectors. NBDHEX can also act as late-phase autophagy inhibitor.

HY-N1987

Cucurbitacin IIb	Apoptosis	Inflammation/Immunology
Cucurbitacin IIb is an active component isolated from Hemsleya amabilis, induces apoptosis with anti-inflammatory activity. Cucurbitacin IIb inhibits phosphorylation of STAT3, JNK and Erk1/2, enhances the phosphorylation of IκB and NF-κB (p65), blocks nuclear translocation of NF-κB (p65) and decreases mRNA levels of IκBα and TNF-α.

HY-13241

Ralimetinib dimesylate LY2228820 dimesylate	p38 MAPK Autophagy Apoptosis	Cancer Inflammation/Immunology
Ralimetinib dimesylate (LY2228820 dimesylate) is a selective, ATP-competitive inhibitor of p38 MAPK α/β with IC₅₀s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38a MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.

HY-N0678

Icaritin Anhydroicaritin	Autophagy Apoptosis	Cancer
Icaritin (Anhydroicaritin) is a prenylflavonoid derivative from Epimedium brevicornuMaxim. and potently inhibits proliferation of K562 cells (IC₅₀ of 8 µM) and primary CML cells (IC₅₀ of 13.4 µM for CML-CP and 18 µM for CML-BC). Icaritin can regulate *MAPK/ERK/JNK* and JAK2/STAT3 /AKT signalings, also enhances osteogenesis^[3.

HY-121983

CAY10594	Phospholipase	Cancer
CAY10594 is a potent phospholipase D2 (PLD2) inhibitor both in vitro (IC₅₀=140 nM) and in cells (IC₅₀=110 nM). CAY10594 strongly inhibits the invasive migration of breast cancer cells in vitro and ameliorates acetaminophen-induced acute liver injury by regulating the phosphorylated-GSK-3β/JNK axis.

HY-13241A

Ralimetinib LY2228820	p38 MAPK Autophagy	Cancer Inflammation/Immunology
Ralimetinib (LY2228820) is a potent and selective, ATP-competitive inhibitor of p38 MAPK α/β, with IC₅₀s of 5.3 and 3.2 nM, respectively. Ralimetinib (LY2228820) selectively inhibits phosphorylation of MK2 (Thr334), with no effect on phosphorylation of p38α MAPK, JNK, ERK1/2, c-Jun, ATF2, or c-Myc.

HY-124421

5F-203 NSC-703786	Aryl Hydrocarbon Receptor	Others
5F-203 (NSC-703786) is a cytotoxic molecule that forms DNA adducts and cell cycle arrest. 5F-203 induces aryl hydrocarbon receptor (AhR) signaling and elevates expression of CYP1A1. 5F-203 also increases the levels of reactive oxygen species as well as activates JNK, ERK, and p38.

HY-151802

CPUL1	TrxR	Cancer
CPUL1 is a TrxR inhibitor, which shows proliferation-inhibitory and anti-metastatic activity against A549 cells. CPUL1 influences EMT (epithelial-mesenchymal transition) via inducing ROS-mediated *ERK/JNK* signaling by inhibiting TrxR1 enzyme activity. CPUL1 in combination with α-Lipoic Acid (HY-N0492) or Dithiodipropionic acid (HY-W014395) is more effective.

HY-W009731

Dibenzoylmethane	Keap1-Nrf2	Cancer Metabolic Disease
Dibenzoylmethane, a minor ingredient in licorice, activates Nrf2 and prevents various cancers and oxidative damage. Dibenzoylmethane, an analog of curcumin, results in dissociation from Keap1 and nuclear translocation of Nrf2.

HY-15496

E6201 ER-806201	MEK FLT3	Cancer
E6201 (ER-806201) is an ATP-competitive dual kinase inhibitor of MEK1 and FLT3. E6201 inhibits MEK1- induced ERK2 phosphorylation with an IC₅₀ value of 5.2 nM, MKK4-induced JNK phosphorylation with an IC₅₀ value of 91 nM, and MKK6-induced p38 MAPK phosphorylation with an IC₅₀ value of 19 nM. Anti-tumor and anti-psoriasis efficacy.

HY-W018643

Ferulic acid methyl ester Methyl ferulate	p38 MAPK Autophagy	Inflammation/Immunology Neurological Disease Cancer
Ferulic acid methyl ester (Methyl ferulate) is a derivative of ferulic acid, isolated from Stemona tuberosa, with anti-inflammatory and antioxidant properties. Ferulic acid methyl ester is a cell membrane and brain permeable compound, shows free radical scavenging ability, used in the research of neurodegenerative disorders. Ferulic acid methyl ester inhibits COX-2 expression, blocks p-p38 and p-JNK in primary bone marrow derived-macrophages.

HY-N0619

Mulberroside A	TNF Receptor Interleukin Related Tyrosinase	Inflammation/Immunology
Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.). Mulberroside A decreases the expressions of TNF-α, IL-1β, and IL-6 and inhibits the activation of NALP3, caspase-1, and NF-κB and the phosphorylation of ERK, JNK, and p38, exhibiting anti-inflammatory antiapoptotic effects. Mulberroside A shows inhibitory activity against mushroom tyrosinase with an IC₅₀ of 53.6 μM.

HY-13811

NSC697923	E1/E2/E3 Enzyme Apoptosis	Cancer
NSC697923 is a potent UBE2N (ubiquitin-conjugating enzyme E2 N, Ubc13) inhibitor. NSC697923 induces neuroblastoma (NB) cell death via promoting nuclear importation of p53 in p53 wild-type NB cells. NSC697923 also induces cell death in p53 mutant NB cells by activation of JNK-mediated apoptotic pathway. NSC697923 inhibits DNA damage and NF-κB signaling. Antitumor activity.

HY-N3364

Lucidone	TNF Receptor NF-κB NO Synthase COX JNK p38 MAPK IKK	Infection Inflammation/Immunology
Lucidone, an anti-inflammatory agent that can be isolated from the fruit of Lindera erythrocarpa Makino. Lucidone inhibits LPS-induced NO and PGE₂ production in RAW 264.7 mouse macrophages. Lucidone also decreases TNF-α secretion, iNOS and COX-2 expression. Lucidone prevents NF-κB translocation and inhibits *JNK* and p38MAPK signals. Lucidone also has inhibitory activity against Dengue virus (DENV) (EC₅₀=25 μM).

HY-N1429

Taurochenodeoxycholic acid sodium 12-Deoxycholyltaurine sodium	Apoptosis Endogenous Metabolite	Inflammation/Immunology
Taurochenodeoxycholic acid (12-Deoxycholyltaurine) sodium is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid sodium induces apoptosis and shows obvious anti-inflammatory and immune regulation properties.

HY-17437

Mefloquine Mefloquin	Parasite Autophagy SARS-CoV Potassium Channel ROS Kinase	Cancer Infection Metabolic Disease Inflammation/Immunology
Mefloquine (Mefloquin), an orally active and potent quinoline antimalarial agent, is an anti-SARS-CoV-2 entry inhibitor. Mefloquine is also a K⁺ channel (KvQT1/minK) antagonist with an IC₅₀ of ~1 μM. Mefloquine can be used for malaria, systemic lupus erythematosus and cancer research.

HY-123942

Diprovocim	Toll-like Receptor (TLR) TNF Receptor p38 MAPK NF-κB	Cancer Inflammation/Immunology
Diprovocim is a potent TLR1/TLR2 agonist. Diprovocim elicits full agonist activity in human THP-1 cells (EC₅₀=110 pM). Diprovocim stimulates the release of TNF-α from mouse macrophages (EC₅₀=1.3 nM). Diprovocim activates downstream MAPK and NF-κB signaling pathway. Diprovocim displays strong adjuvant activity in mice, particularly abetting cellular immune responses.

HY-N2027

Taurochenodeoxycholic acid 12-Deoxycholyltaurine	Apoptosis Endogenous Metabolite	Inflammation/Immunology
Taurochenodeoxycholic acid (12-Deoxycholyltaurine) is one of the main bioactive substances of animals' bile acid. Taurochenodeoxycholic acid induces apoptosis and shows obvious anti-inflammatory and immune regulation properties.

HY-150596

CT1-3	Apoptosis Bcl-2 Family JNK	Cancer
CT1-3 is a potent anticancer agent. CT1-3 induces mitochondria-mediated apoptosis by regulating *JNK/Bcl-2/Bax/XIAP* pathway. CT1-3 suppresses the epithelial mesenchymal transition (EMT) potential of human cancer cells (HCCs) via regulating the E-cadherin/Snail axis, thus inhibits tumorigenesis. CT1-3 has a strong antitumor effect in mice model and exhibits no significant hepatic and renal toxicity.

HY-N0619A

cis-Mulberroside A Mulberroside D	TNF Receptor Interleukin Related Tyrosinase	Inflammation/Immunology
cis-Mulberroside A (Mulberroside D) is the cis-isomer of Mulberroside A. Mulberroside A is one of the main bioactive constituent in mulberry (Morus alba L.). Mulberroside A decreases the expressions of TNF-α, IL-1β, and IL-6 and inhibits the activation of NALP3, caspase-1, and NF-κB and the phosphorylation of ERK, JNK, and p38, exhibiting anti-inflammatory and anti-apoptotic effects. Mulberroside A shows inhibitory activity against mushroom tyrosinase with an IC₅₀ of 53.6 μM.

HY-B0239

Chloramphenicol	Antibiotic Bacterial HIF/HIF Prolyl-Hydroxylase VEGFR Autophagy Apoptosis Beclin1 JNK Akt MMP	Cancer Infection
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research.

HY-10256

Adezmapimod SB 203580; RWJ 64809	p38 MAPK Autophagy Mitophagy	Inflammation/Immunology Cancer
Adezmapimod (SB 203580) is a selective and ATP-competitive p38 MAPK inhibitor with IC₅₀s of 50 nM and 500 nM for SAPK2a/p38 and SAPK2b/p38β2, respectively. Adezmapimod inhibits LCK, GSK3β and PKBα with IC₅₀s of 100-500-fold higher than that for SAPK2a/p38. Adezmapimod does not disrupt JNK activity and is an autophagy and mitophagy activator.

HY-150795

SY-LB-35	TGF-beta/Smad PI3K Akt ERK JNK	Others
SY-LB-35 is a potent bone morphogenetic protein (BMP) receptor agonist. SY-LB-35 can stimulate significant increases in cell number and cell viability in the C2C12 myoblast cell line, and causes shifts towards the S and G2/M phases of the cell cycle. SY-LB-35 stimulates canonical Smad and non-canonical PI3K/Akt, ERK, p38 and *JNK* intracellular signaling pathways.

HY-151431

Nrf2/HO-1 activator 2	Keap1-Nrf2 Reactive Oxygen Species ERK Akt JNK	Neurological Disease
Nrf2/HO-1 activator 2 (compound 13m), difluoro-substituted derivative, is a potent Nrf2/HO-1 activator. Nrf2/HO-1 activator 2 has neuroprotective and antioxidant effects through the Nrf2/HO-1 pathway mediated by phosphorylation of ERK1/2, JNK, or Akt in PC12 cells. Nrf2/HO-1 activator 2 can be used in the research of Parkinson's disease (PD).

HY-112457

MK2-IN-3 hydrate	MAPKAPK2 (MK2)	Inflammation/Immunology
MK2-IN-3 hydrate (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC₅₀ of 0.85 nM.MK2-IN-3 hydrate is exceptional selectivity against MK-3 (IC₅₀=0.21 μM), MK-5 (IC₅₀=0.081 μM), ERK2 (IC₅₀=3.44 μM), MNK1(IC₅₀=5.7 μM) as well as CDK2, JNK2, IKK2, MSK1, and MSK2.

HY-107738

Guggulsterone Z/E-Guggulsterone	Apoptosis JNK Akt Caspase FXR Autophagy	Cancer
Guggulsterone is a plant sterol derived from the gum resin of the tree Commiphora wightii. Guggulsterone inhibits the growth of a wide variety of tumor cells and induces apoptosis through down regulation of antiapoptotic gene products (IAP1, xIAP, Bfl-1/A1, Bcl-2, cFLIP and survivin), modulation of cell cycle proteins (cyclin D1 and c-Myc), activation of caspases and JNK, inhibition of Akt. Guggulsterone, a farnesoid X receptor (FXR) antagonist, decreases CDCA-induced FXR activation with IC₅₀s of 17 and 15 μM for Z- and E-Guggulsterone, respectively.

HY-122872

MKK7-COV-9	p38 MAPK	Cancer
MKK7-COV-9 is a potent and selective covalent inhibitor of MKK7 and targets a specific protein–protein interaction of MKK7. MKK7-COV-9 blocks primary B cell activation in response to LPS with an EC₅₀ of 4.98 μM.

HY-141645

IMM-H007 WS070117	AMPK TGF-β Receptor NF-κB JNK AP-1	Metabolic Disease Inflammation/Immunology Cardiovascular Disease
IMM-H007 (WS070117) is an orally active and potent AMPK (AMP-activated protein kinase) activator and TGFβ1 (transforming growth factor β1) antagonist. IMM-H007 has protective effects in cardiovascular diseases via activation of AMPK. IMM-H007 negatively regulates endothelium inflammation through inactivating NF-κB and *JNK/AP1* signaling. IMM-H007 inhibits ABCA1 degradation. IMM-H007 resolves hepatic steatosis in HFD-fed hamsters by the regulation of lipid metabolism. IMM-H007 can be used for the research of nonalcoholic fatty liver disease (NAFLD) and inflammatory atherosclerosis.

HY-131249

MK2-IN-3	MAPKAPK2 (MK2)	Inflammation/Immunology
MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC₅₀ of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC₅₀s=0.21, 0.081, 3.44, 5.7, and >100 μM, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC₅₀s>200 μM). MK2-IN-3 can reduce TNFα production in both U937 cells and in vivo.

HY-10341

Fasudil Hydrochloride HA-1077 Hydrochloride; AT-877 Hydrochloride	ROCK Calcium Channel Autophagy PKA PKC HIV	Cancer
Fasudil (HA-1077; AT877) Hydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil Hydrochloride is also a potent Ca²⁺ channel antagonist and vasodilator.

HY-10341C

Fasudil dihydrochloride HA-1077 dihydrochloride; AT-877 dihydrochloride	Calcium Channel ROCK PKA PKC Autophagy HIV	Cancer
Fasudil (HA-1077; AT877) dihydrochloride is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil dihydrochloride is also a potent Ca²⁺ channel antagonist and vasodilator.

HY-10341B

Fasudil hydrochloride semihydrate HA-1077 hydrochloride semihydrate; AT877 hydrochloride semihydrate	ROCK Calcium Channel Autophagy HIV PKA PKC	Cancer
Fasudil (HA-1077; AT877) hydrochloride semihydrate is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil hydrochloride semihydrate is also a potent Ca²⁺ channel antagonist and vasodilator.

HY-10341A

Fasudil HA-1077; AT877	ROCK Calcium Channel Autophagy PKA PKC	Cancer
Fasudil (HA-1077; AT877) is a nonspecific RhoA/ROCK inhibitor and also has inhibitory effect on protein kinases, with an K_i of 0.33 μM for ROCK1, IC₅₀s of 0.158 μM and 4.58 μM, 12.30 μM, 1.650 μM for ROCK2 and PKA, PKC, PKG, respectively. Fasudil is also a potent Ca²⁺ channel antagonist and vasodilator.

Cat. No.	Product Name

HY-L010

MAPK Compound Library

344 compounds

MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers.

MCE designs a unique collection of 344 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

Cat. No.	Product Name	Target	Research Area